Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

The Cardiovascular Link to Nonalcoholic Fatty Liver Disease

(2012) Tommy Pacana et al.   Clinics in Liver Disease

Insulin signaling to hepatic lipid metabolism in health and disease

(2011) Karla F. Leavens et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus

(2011) Baptist Gallwitz   DRUGS

C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients

(2011) Esther Zimmermann et al.   JOURNAL OF HEPATOLOGY

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

(2011) Gianluca Svegliati-Baroni et al.   LIVER INTERNATIONAL

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis

(2011) Lisa B. Van Wagner et al.   Therapeutic Advances in Gastroenterology

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

(2010) M. C. Bunck et al.   DIABETES CARE

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

(2010) Giovanni Musso et al.   HEPATOLOGY

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of Diabetes among Men and Women in China

(2010) Wenying Yang et al.   NEW ENGLAND JOURNAL OF MEDICINE

New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)

(2009) Rafeeq Ali et al.   ANNALS OF MEDICINE